Irene S. Yu

Irene S. Yu

Auto-generated profile, based on publicly available information

Irene S. Yu

BC Cancer Agency, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2022 in Heliyon
Verified
Journal Article
Open access
AMAngela S. Mathews
Angela S. Mathews
APAshley Paul
Ashley Paul
IYIrene S. Yu
Irene S. Yu
CMColleen McGahan
Colleen McGahan
EBEric Bhang
Eric Bhang
JLJonathan M Loree
Jonathan M Loree
We evaluated survival outcomes for patients with cancer and COVID-19 in this population-based study. A total of 631 patients who tested positive for severe acute respiratory syndrome coronavirus 2 and were seen at BC Cancer between 03/03/2020 and 01/21/2021 were included, of whom 506 had a diagnosis of cancer and PCR-confirmed positive test for coronavirus disease 2019. Patient clinical characteristics were retrospectively reviewed and the influence of demographic data, cancer diagnosis, comorbidities, and anticancer treatment(s) on survival following severe acute respiratory syndrome coronavirus 2 infection were analyzed. Age ≥65 years (Hazard Ratio [HR] 4.77, 95% Confidence Interval [CI] 2.72–8.35, P < 0.0001), those with Eastern Cooperative Oncology Group Performance Status ≥2 (HR 8.36, 95% CI 2.89–24.16, P < 0.0001), hypertension (HR 3.17, 95% CI 1.77–5.66, P < 0.0001), and metastatic/advanced stage (HR 3.70, 95% CI 1.77–7.73, P < 0.0001) were associated with worse coronavirus disease 2019 specific survival outcomes following severe acute respiratory syndrome coronavirus 2 infection. Patients with lung cancer had the highest 30-day COVID-19 specific mortality (25.0%), followed by genitourinary (18.1%), gastrointestinal (16.0%), and other cancer types (<10.0%). Patients with the highest 30-day coronavirus disease 2019 specific mortality according to treatment type were those on chemotherapy (23.0%), rituximab (22.2%), and immunotherapy (16.7%) while patients on hormonal treatments (2.2%) had better survival outcomes (P = 0.041) compared to those on other anticancer treatments. This study provides further evidence that patients with cancer are at increased risk of mortality from coronavirus disease 2019 and emphasizes the need for vaccination.

1 June 2022 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
IYIrene S. Yu
Irene S. Yu
ZAZamzam Al-Hashami
Zamzam Al-Hashami
PCParv Chapani
Parv Chapani
CSCaroline Speers
Caroline Speers
JDJanine M. Davies
Janine M. Davies
JLJonathan M Loree
Jonathan M Loree

4 February 2021 in The Oncologist
Verified
Journal Article
Open access
PDF file
IYIrene S. Yu
Irene S. Yu
JLJonathan M Loree
Jonathan M Loree
This commentary focuses on the results of the study by Pietrantonio et al., which evaluated the clinical conundrum of triplet versus doublet chemotherapy in combination with targeted therapy for metastatic left‐sided RAS/BRAF wild‐type colorectal cancer and appears in this issue. Both FOLFOXIRI [fluorouracil, leucovorin, oxaliplatin, and irinotecan] plus bevacizumab and FOLFOX [fluorouracil, leucovorin, and oxaliplatin] plus panitumumab have shown impressive activity in this population; however, the two have not been directly compared. The article by Pietrantonio et al. presents a propensity score‐adjusted analysis using information from five previous randomized trials and provides best available evidence comparing these regimens. This commentary will discuss their results and how their findings fit in current treatment paradigms.

30 September 2021 in Surgery Case Reports
Verified
Journal Article
Open access
PDF file
JIJohn Petrie Iv
John Petrie Iv
AMArvind Manisundaram
Arvind Manisundaram
IYIrene Yu
Irene Yu
SSSteven Schwaitzberg
Steven Schwaitzberg
Introduction: A 46-year-old female with a past medical history of Graves’ disease refractory to medical management, thus requiring total thyroidectomy presented to clinic for recurrence of her hyperthyroidism and an increasing midline neck mass two years after her index operation. Case Description: CT imaging of the neck mass revealed a locally extensive enhancing abnormality immediately anterior to the hyoid bone within the infrahyoid muscles measuring 1.4x.1.9x4.0 cm. This was consistent with an exceedingly rare proliferation of a thyroglossal duct remnant secondary to recurrence of the patient’s Graves’ disease. The patient was treated with surgical resection of the neck mass shown to be ectopic Graves’ activated thyroid tissue by pathology. The patient was restarted on thyroid hormone replacement therapy and has remained euthyroid to date following surgical resection. Conclusion: The incidence of this event is estimated to be approximately one per a million persons and thus is a rare occurrence in endocrinology. This case highlights the potential shortcomings of surgical management of Graves’ disease. Following surgical resection, the autoimmune status of the patient remains unchanged. Ectopic thyroid tissue can be found anywhere along the embryologic descent of the thyroid gland and as low as the mediastinum. Thus, patients treated with total thyroidectomy should still be monitored regularly for recurrence of Graves’ disease secondary to ectopic thyroid tissue.